World News: 22:15 GMT Monday 11th February 2019. [Immunomedics via Globe Newswire via SPi World News]
MORRIS PLAINS, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- , (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that updated data with longer follow-up on sacituzumab govitecan, its lead investigational ADC, in patients with metastatic urothelial cancer (mUC) who have relapsed or are refractory to chemotherapies and immune checkpoint inhibitors (CPIs), have been accepted for an oral presentation at this year’s Genitourinary Cancers Symposium (ASCO-GU).
As reported in the abstract released online, sacituzumab govitecan produced an overall response rate (ORR) of 31 percent in 45 heavily-pretreated mUC patients, with an encouraging median duration of response of 12.6 months and median progression-free survival of 7.3 months. Consistent with prior reports, the updated safety profile demonstrates that sacituzumab govitecan is generally well tolerated and manageable relative to other available therapies. Further data on subgroups will be presented at the meeting.
“Despite the late-stage setting, sacituzumab govitecan continues to show promising activity in patients who failed current standard of care for mUC,” said Dr. Robert Iannone, Head of Research & Development and Chief Medical Officer of Immunomedics. “We believe these results support further investigation in a pivotal Phase 2 TROPHY U-01 study.
The trial design of TROPHY U-01 is the subject of the second presentation at ASCO-GU. Details of the two presentations are listed below (all times are in Pacific Time):
Friday, February 15, 2019
Globe Newswire: 22:15 GMT Monday 11th February 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.